Clinical Trial

Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

Recruiting
View on ClinicalTrials.gov →
Summary
22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2007-11-08; most recent amendment 2025-07-17.
Status change: Active, Not Recruiting → Recruiting 2020-08-28
Status change: Recruiting → Active, Not Recruiting 2017-01-23
Trial Details
NCT Number NCT00556530
Lead Sponsor Albert Einstein College of Medicine
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Children's Hospital of Philadelphia, University of Geneva, Switzerland, University of Toronto, Bambino Gesù Children's Hospital IRCCS, University of California, Los Angeles, Cardiff University, Universidad del Desarrollo, Tel Aviv University, KU Leuven, Maastricht University, The Coriell Institute, National Institute on Aging (NIA), Center for Inherited Disease Research (CIDR)
Conditions DiGeorge Syndrome, 22q11.2 Deletion Syndrome
Enrollment 1,000 participants
Start Date 2016-07
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-29